The three clinical partners of the m-RESIST group have been working on a document to identify and compare available health care resources in Israel, Hungary and Spain.

During the first 6 months of the project, one of the m-RESIST activities performed was to describe the available health care resources and pathways of care for the most common problems of treatment-resistant schizophrenia, and how it was anticipated that the m-RESIST service would be provided.

The output of this activity was documented in “m-RESIST services and care pathways” report. This contained a detailed description of the current services available in each of the 3 countries were pilots will be developed, and the new or improved care services to be delivered.

Although the availability of services was shown to be different in each country, most of the services provided were similar, suggesting that the implementation of the m-RESIST solution could be performed in a parallel way in the three countries.

Also this activity reflected that the interaction between services is similar in each of the three countries, which is helpful to implement the m-RESIST programme in a similar way regarding the interactions between the networks of available services in each country. In spite of the similarities between health care services, this activity also noted the heterogeneity in the different databases, which will be one of the challenges of successful implementation of m-RESIST.

The conclusion of this analyses of health care resources in Israel, Hungary and Spain, highlighted the feasibility of m-RESIST being implemented in several services common to the 3 countries. Nevertheless, the output of this activity also noted that m-RESIST should be considered as a new integrated digital service delivered to patients with treatment-resistant schizophrenia, and therefore, a new care pathway development is essential to guaranteeing successful deployment of this solution.